• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

影响麻疹疫苗效力、效果和免疫原性因素的系统评价与模型分析见解

A systematic review and modelling insights of factors impacting measles vaccine effectiveness, efficacy and immunogenicity.

作者信息

Ghosh Samiran, Kappara Divya, Majumder Nabanita, Nath-Sain Suchita, Roy Arup Deb, Mukhopadhyay Siuli

机构信息

Department of Mathematics, Indian Institute of Technology, Bombay, Mumbai, Maharashtra 400076 India.

National Disease Modelling Consortium, Indian Institute of Technology, Bombay, Mumbai, 400076 Maharashtra India.

出版信息

Discov Viruses. 2025;2(1):23. doi: 10.1007/s44370-025-00027-8. Epub 2025 Aug 28.

DOI:10.1007/s44370-025-00027-8
PMID:40918614
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12412780/
Abstract

INTRODUCTION

Outbreaks of measles have been frequently reported despite the availability of an effective vaccine. In this systematic review we examine the potential factors that could impact the effectiveness, efficacy and immunogenicity of the measles vaccine (MV) in children.

METHODS

We conducted a literature search using PubMed and Google Scholar for primary articles published between January 2010 and April 2025. Articles reporting the effectiveness, efficacy or immunogenicity of MV in children aged 0-15 years were included. Additionally, we use regression analysis on data available from few cohort studies in India and epidemiological modelling simulations to assess the effect of factors on vaccine effectiveness (VE), efficacy and immunogenicity.

RESULTS

Overall, 48 primary articles involving 172,464 children who had received the MV were included in the analysis. Key factors that may affect VE, efficacy and immunogenicity were malnutrition, genetic variants, chemotherapy and gender. Through statistical modelling we identified an inverse relationship between malnutrition and measles VE and estimated the possible percentage decrease in VE due to malnutrition across different states of India. Additionally, simulations from a Susceptible-Infected type model showed the effect of varying VE on the modelling outcomes and measles elimination targets.

CONCLUSIONS

We identified a few key factors including malnutrition, genetic variants, chemotherapy and gender that impact measles VE, efficacy and immunogenicity. Therefore, in addition to maintaining WHO recommended vaccine coverages, addressing the problems related to vaccine performance, evaluated in terms of VE, efficacy and immunogenicity, is crucial for achieving measles elimination targets.

SUPPLEMENTARY INFORMATION

The online version contains supplementary material available at 10.1007/s44370-025-00027-8.

摘要

引言

尽管有有效的疫苗,但麻疹疫情仍时有报道。在本系统评价中,我们研究了可能影响儿童麻疹疫苗(MV)有效性、效力和免疫原性的潜在因素。

方法

我们使用PubMed和谷歌学术搜索了2010年1月至2025年4月发表的主要文章。纳入了报告MV在0至15岁儿童中有效性、效力或免疫原性的文章。此外,我们对印度少数队列研究可得的数据进行回归分析,并进行流行病学建模模拟,以评估各因素对疫苗有效性(VE)、效力和免疫原性的影响。

结果

总体而言,分析纳入了48篇主要文章,涉及172464名接种过MV的儿童。可能影响VE、效力和免疫原性的关键因素包括营养不良、基因变异、化疗和性别。通过统计建模,我们确定了营养不良与麻疹VE之间的反比关系,并估计了印度不同邦因营养不良导致的VE可能下降的百分比。此外,易感-感染型模型的模拟显示了不同VE对建模结果和麻疹消除目标的影响。

结论

我们确定了一些关键因素,包括营养不良、基因变异、化疗和性别,它们会影响麻疹的VE、效力和免疫原性。因此,除了维持世界卫生组织建议的疫苗接种覆盖率外,解决与疫苗性能相关的问题(从VE、效力和免疫原性方面评估)对于实现麻疹消除目标至关重要。

补充信息

在线版本包含可在10.1007/s44370-025-00027-8获取的补充材料。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1712/12412780/f6042a3f7cd6/44370_2025_27_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1712/12412780/35e5bb656258/44370_2025_27_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1712/12412780/348f2b7de921/44370_2025_27_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1712/12412780/95e954e5e37a/44370_2025_27_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1712/12412780/f6042a3f7cd6/44370_2025_27_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1712/12412780/35e5bb656258/44370_2025_27_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1712/12412780/348f2b7de921/44370_2025_27_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1712/12412780/95e954e5e37a/44370_2025_27_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1712/12412780/f6042a3f7cd6/44370_2025_27_Fig4_HTML.jpg

相似文献

1
A systematic review and modelling insights of factors impacting measles vaccine effectiveness, efficacy and immunogenicity.影响麻疹疫苗效力、效果和免疫原性因素的系统评价与模型分析见解
Discov Viruses. 2025;2(1):23. doi: 10.1007/s44370-025-00027-8. Epub 2025 Aug 28.
2
Immunogenicity and seroefficacy of pneumococcal conjugate vaccines: a systematic review and network meta-analysis.肺炎球菌结合疫苗的免疫原性和血清效力:系统评价和网络荟萃分析。
Health Technol Assess. 2024 Jul;28(34):1-109. doi: 10.3310/YWHA3079.
3
Oral killed cholera vaccines for preventing cholera.口服霍乱疫苗预防霍乱。
Cochrane Database Syst Rev. 2024 Jan 10;1(1):CD014573. doi: 10.1002/14651858.CD014573.
4
Estimating the health effects of COVID-19-related immunisation disruptions in 112 countries during 2020-30: a modelling study.估算 2020-2030 年期间 112 个国家因与 COVID-19 相关的免疫接种中断对健康产生的影响:建模研究。
Lancet Glob Health. 2024 Apr;12(4):e563-e571. doi: 10.1016/S2214-109X(23)00603-4.
5
Vaccines for measles, mumps, rubella, and varicella in children.儿童麻疹、腮腺炎、风疹和水痘疫苗。
Cochrane Database Syst Rev. 2021 Nov 22;11(11):CD004407. doi: 10.1002/14651858.CD004407.pub5.
6
Efficacy and safety of COVID-19 vaccines.新型冠状病毒疫苗的有效性和安全性。
Cochrane Database Syst Rev. 2022 Dec 7;12(12):CD015477. doi: 10.1002/14651858.CD015477.
7
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
8
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
9
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状Meta分析。
Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3.
10
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.利用预后信息为乳腺癌患者选择辅助性全身治疗的成本效益
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.

本文引用的文献

1
Measles-mumps-rubella-vaccination at 6 months of age induces measles-specific T cell responses: a randomized controlled trial.6月龄时接种麻疹-腮腺炎-风疹疫苗可诱导麻疹特异性T细胞反应:一项随机对照试验。
Front Immunol. 2025 Mar 17;16:1546253. doi: 10.3389/fimmu.2025.1546253. eCollection 2025.
2
Non-inferiority and vaccine titer-confirmation studies of MMR vaccine (JVC-001; measles AIK-C, mumps RIT4385, and rubella Takahashi strains) in healthy 1-year-old Japanese children.对健康的1岁日本儿童进行的MMR疫苗(JVC - 001;麻疹AIK - C株、腮腺炎RIT4385株和风疹高桥株)的非劣效性及疫苗效价确认研究。
Vaccine. 2025 Mar 7;49:126698. doi: 10.1016/j.vaccine.2024.126698. Epub 2025 Feb 6.
3
Genetic associations with measles PRNT and IgG antibody response to MMR vaccination in 6- and 15-month-old children.
6个月和15个月大儿童中与麻疹空斑减少中和试验及MMR疫苗接种的IgG抗体反应的基因关联。
Vaccine. 2025 Mar 19;50:126788. doi: 10.1016/j.vaccine.2025.126788. Epub 2025 Feb 5.
4
Measles vaccine effectiveness in African children: a systematic review and meta-analysis.麻疹疫苗在非洲儿童中的有效性:系统评价和荟萃分析。
BMC Infect Dis. 2024 Nov 21;24(1):1330. doi: 10.1186/s12879-024-10239-w.
5
Long-term Dynamics of Measles Virus-Specific Neutralizing Antibodies in Children Vaccinated Before 12 Months of Age.12月龄前接种疫苗儿童中麻疹病毒特异性中和抗体的长期动态变化
Clin Infect Dis. 2025 Apr 30;80(4):904-910. doi: 10.1093/cid/ciae537.
6
Comparison of measles plaque reduction neutralization test (PRNT) and measles virus-specific IgG ELISA for assessment of immunogenicity of measles-mumps-rubella vaccination at 5-7 months of age and maternal measles antibodies.比较麻疹蚀斑减少中和试验(PRNT)和麻疹病毒特异性IgG ELISA,以评估5至7月龄麻疹-腮腺炎-风疹疫苗接种的免疫原性及母体麻疹抗体。
Vaccine X. 2024 Aug 16;20:100548. doi: 10.1016/j.jvacx.2024.100548. eCollection 2024 Oct.
7
Long-term persistence of seroprotection against measles following measles-mumps-rubella vaccination administered before and after pediatric liver transplantation.小儿肝移植前后接种麻疹-腮腺炎-风疹疫苗后对麻疹血清保护的长期持续性
Am J Transplant. 2025 Jan;25(1):170-180. doi: 10.1016/j.ajt.2024.07.017. Epub 2024 Jul 18.
8
Assessing seropositivity of MMR antibodies in individuals aged 2-22: evaluating routine vaccination effectiveness after the 2003 mass campaign-a study from Iran's National Measles Laboratory.评估 2-22 岁个体的 MMR 抗体血清阳性率:2003 年大规模接种运动后评估常规疫苗接种效果-来自伊朗国家麻疹实验室的研究。
BMC Infect Dis. 2024 Jul 12;24(1):696. doi: 10.1186/s12879-024-09593-6.
9
Phase III, open-label, single-arm study of a new MMR vaccine (JVC-001); measles AIK-C, mumps RIT 4385, rubella Takahashi, as a second vaccine dose in healthy Japanese children aged 5-6 years.一项新型麻疹、腮腺炎、风疹联合疫苗(JVC-001)的 III 期、开放性、单臂研究;麻疹 AIK-C、腮腺炎 RIT4385、风疹 Takahashi,作为 5-6 岁健康日本儿童的第二剂疫苗。
J Infect Chemother. 2024 Dec;30(12):1289-1294. doi: 10.1016/j.jiac.2024.06.011. Epub 2024 Jun 19.
10
Seroprevalence of Measles (Rubeola) Antibodies in Childhood Cancer Survivors.儿童癌症幸存者麻疹(风疹)抗体的血清阳性率。
J Pediatr Hematol Oncol Nurs. 2024 Sep-Oct;41(5):309-314. doi: 10.1177/27527530231221145. Epub 2024 May 7.